InauguralInvitation Only
Pan-Oncology
USSummit 2027
Three days, 74 people, one room.
October 28 to 30, 2027
Scottsdale, AZ
Dates
October 28-30, 2027
Three-day program
Venue
Scottsdale, AZ
Hotel TBD
Audience
74 by invitation
36 KOLs & 38 fellows
Format
10 sessions · 40 talks
14 fellow-presented cases
Four Tumor Areas, One Room
The Summit convenes the faculty of four separate disease areas at the same table: 36 leading US oncology KOLs across breast, gastrointestinal, lung and genitourinary cancers, alongside 38 hand-selected fellows and junior faculty, for three days in Scottsdale.
Each tumor area runs its own block of dense, perspective-driven sessions. What no single-tumor meeting can offer sits between them: a Cross-Tumor pillar where the questions that cut across disease areas are argued by the people who lead each of them, and a Next Gen block built for the fellows in the room and led by all four chairs together.
For companies with assets in more than one tumor area, this is the only meeting in the portfolio where a single engagement reaches all of them.
Cross-TumorNext GenADC SequencingPerioperative & Adjuvant IOMRD & ctDNAHER2 Across TumorsRAS-Directed Therapy · Radioligand Therapy & PSMA PETBiomarker-Driven Selection · Cardio-Oncology
Summit Co-Chairs
Tanios Bekaii-Saab
Mayo Clinic, Phoenix, AZ
Virginia Kaklamani
UT Health, San Antonio, TX
Stephen Liu
Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.
Rana R. McKay
UC San Diego Health, CA
A Proven Platform, Not a One-Off
The Summit is built on 14 established US Focus Meetings in breast, lung, gastrointestinal and genitourinary cancers, and brings their faculty together for the first time.
74
Invited attendees only, sustained access, not a crowd
4
Tumor areas in one room: breast, gastrointestinal, lung and genitourinary
14
Established US Focus Meetings behind it, a proven platform, not a one-off
Pan-Oncology US Summit 2027
Faculty
Listed alphabetically by surname
Neeraj Agarwal
Huntsman Cancer Institute, Salt Lake City, UT
Emmanuel Antonarakis
University of Minnesota, Minneapolis, MN
Tanios Bekaii-Saab
Mayo Clinic, Phoenix, AZ
Tina Cascone
MD Anderson Cancer Center, Houston, TX
Mariana Chavez-MacGregor
MD Anderson Cancer Center, Houston, TX
Yu-Wei Chen
UC San Diego, La Jolla, CA
Cristina Ferrone
Cedars-Sinai, Los Angeles, CA
Richard Finn
UCLA, Santa Monica, CA
Carla Fisher
Indiana University School of Medicine, Indianapolis, IN
Narjust Florez
Dana-Farber Cancer Institute, Boston, MA
Justin Gainor
Massachusetts General Hospital, Boston, MA
Marina Garassino
University of Chicago Medicine, Chicago, IL
Shilpa Gupta (TBC)
Cleveland Clinic, Cleveland, OH
Balazs Halmos
Albert Einstein College of Medicine, Bronx, NY
James Harding
Memorial Sloan Kettering, New York, NY
Yelena Janjigian
Memorial Sloan Kettering, New York, NY
Virginia Kaklamani
UT Health, San Antonio, TX
Samuel Klempner
Massachusetts General Hospital, Boston, MA
Ben Levy
Johns Hopkins Medicine, Baltimore, MD
Stephen Liu
Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.
Marcela Mazo Canola
UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Heather McArthur
UT Southwestern Medical Center, Dallas, TX
Bradley McGregor
Dana-Farber Cancer Institute, Boston, MA
Rana R. McKay
UC San Diego Health, CA
Shanu Modi
Memorial Sloan Kettering, New York, NY
Todd Morgan
University of Michigan, Ann Arbor, MI
Mamta Parikh
UC Davis Comprehensive Cancer Center, Sacramento, CA
Sandip Patel
UC San Diego, La Jolla, CA
Bruna Pellini (TBC)
Miami Cancer Institute, Baptist Health, Miami, FL
Sonya Reid
Vanderbilt University Medical Center, Nashville, TN
Jonathan Riess (TBC)
UC Davis Comprehensive Cancer Center, Sacramento, CA
Christian Rolfo
Ohio State University, Columbus, OH
Julia Rotow
Dana-Farber Cancer Institute, Boston, MA
John Strickler
Duke Cancer Institute, Durham, NC
Alexandra Thomas
Duke Cancer Institute, Durham, NC
Alastair Thompson
Baylor College of Medicine, Houston, TX
Phuoc Tran
MD Anderson Cancer Center, Houston, TX
Heather Wakelee
Stanford University, Stanford, CA
Brian Wolpin
Dana-Farber Cancer Institute, Boston, MA
Christina Wu (TBC)
Mayo Clinic, Phoenix, AZ
Three Days, Ten Sessions
Agenda
15 min
5 min
30 min
20 min
65 min
Day One · Thursday, October 28, 2027 · Genitourinary & Breast
Ohio State University, Columbus, OH
Session IGenitourinary Cancers
ModeratorTBD
Metastatic mCRPC: Treatment Selection by Prior Therapy Exposure, PARP Combinations, Radioligand Therapy, Taxanes, and Biomarker Testing
Emmanuel AntonarakisUniversity of Minnesota, Minneapolis, MN
Localized Prostate Cancer: Risk Stratification, Selecting Among Definitive Treatment Options, and Who Benefits from Intensification
Todd MorganUniversity of Michigan, Ann Arbor, MI
Biochemical Recurrence: Imaging-First Evaluation with PSMA PET, Metastasis-Directed Therapy, and When to Start Systemic Therapy
Phuoc TranMD Anderson Cancer Center, Houston, TX
Metastatic mHSPC: Doublets, Triplets, and Tailoring Intensification to Volume and Biology
Neeraj AgarwalHuntsman Cancer Institute, Salt Lake City, UT
Panel Discussion
Coffee Break
Session IIGenitourinary Cancers
ModeratorTBD
Advanced Clear Cell RCC: Frontline IO Combinations, Sequencing After Progression, and HIF-2α Inhibition
Yu-Wei ChenUC San Diego, La Jolla, CA
Localized and Locally Advanced RCC: Risk Stratification and Adjuvant Therapy Decisions
Bradley McGregorDana-Farber Cancer Institute, Boston, MA
Metastatic Urothelial Carcinoma: Enfortumab Vedotin–Pembrolizumab, ADC Sequencing, and Toxicity Management
Mamta ParikhUC Davis Comprehensive Cancer Center, Sacramento, CA
Panel Discussion
Session IXBreast Cancer
ModeratorTBD
Cardiooncology: How to Evaluate the Heart
Alexandra ThomasDuke Cancer Institute, Durham, NC
Optimal Treatment of High Risk HR+ Early Breast Cancer
Sonya ReidVanderbilt University Medical Center, Nashville, TN
Omitting Axillary Surgery: Pushing the Limits
Carla FisherIndiana University School of Medicine, Indianapolis, IN
Panel Discussion
Coffee Break
Session XBreast Cancer
ModeratorTBD
Updates in Immunotherapy in the Treatment of Breast Cancer
Heather McArthurUT Southwestern Medical Center, Dallas, TX
Should We Incorporate Maintenance Therapy in HER2+ MBC?
Mariana Chavez-MacGregorMD Anderson Cancer Center, Houston, TX
ADCs: How Can We Improve on What We Already Have?
Shanu ModiMemorial Sloan Kettering, New York, NY
The Optimal Treatment of Early Stage HER2 Pos Breast Cancer
Marcela Mazo CanolaUT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Panel Discussion
Day Two · Friday, October 29, 2027 · Cross-Tumor & Next Gen
Agenda & Faculty to be Announced
ModeratorTBC
HRD+ Use of PARP Inhibitors
Ying LiuMemorial Sloan Kettering, New York, NY
HRD Test Negative: Bev vs No Bev; Trials to Watch
David O’MalleyOhio State University, Columbus, OH
Low-Grade Ovarian Cancer
Jubilee BrownAtrium Health Levine Cancer Institute, Charlotte, NC
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
Beyond PARP: The Replication-Stress Axis (ATR/WEE1/PKMYT1/CCNE1)
Timothy YapMD Anderson Cancer Center, Houston, TX
ADCs in PSOC and PROC: Mechanisms of Resistance
Rebecca PorterDana-Farber Cancer Institute, Boston, MA
Other Modalities in PROC: Working Up & Sequencing Options
John ChanSutter Health/Palo Alto Medical Foundation, San Francisco, CA
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
Local Regional Treatment, ICI & Unanswered Questions
Jyoti MayadevUC San Diego, La Jolla, CA
1st-Line Metastatic & Opportunities to Improve
Krishnansu TewariUC Irvine, Orange, CA
2L ADCs: Finally Something That Works
Ritu SalaniUCLA, Los Angeles, CA
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
TCEs & Bispecifics
Oladapo YekuMassachusetts General Hospital, Boston, MA
Novel Small Molecules: KIF18A and Others
Shannon WestinMD Anderson Cancer Center, Houston, TX
ADCs with Multiple Targets and/or Multiple Payloads: Hope versus Hype
Patricia LoRussoYale Cancer Center, New Haven, CT
Young Investigator Case Presentation
TBD
Panel Discussion
Day Three · Saturday, October 30, 2027 · Gastrointestinal & Lung
Session IIIGastrointestinal Cancers
ModeratorTBD
The Many Ways for Targeting RAS in Pancreas Cancer
Brian WolpinDana-Farber Cancer Institute, Boston, MA
Perioperative Strategies in Early Stage Pancreas Cancer: An Evolving Landscape
Cristina FerroneCedars-Sinai, Los Angeles, CA
HER2 as a Target in Gastroesophageal Cancer: First Line and Sequencing Strategies
Samuel KlempnerMassachusetts General Hospital, Boston, MA
Perioperative Strategies in Gastroesophageal Cancer: Who and What?
Yelena JanjigianMemorial Sloan Kettering, New York, NY
Panel Discussion
Coffee Break
Session IVGastrointestinal Cancers
ModeratorTBD
The Evolution of the Treatment Landscape of Patients with Biliary Tract Cancers
James HardingMemorial Sloan Kettering, New York, NY
The Rise of Targeted Therapies in First Line Treatment of mCRC
John StricklerDuke Cancer Institute, Durham, NC
The Role of Systemic Therapeutic Strategies in Unresectable Embolization Eligible HCC
Richard FinnUCLA, Santa Monica, CA
Panel Discussion
Session VIILung Cancer
ModeratorTBD
Evolving Standards in Perioperative Immunotherapy for NSCLC
Tina CasconeMD Anderson Cancer Center, Houston, TX
Rewriting Paradigms: Best Practice for Advanced SCLC
Balazs HalmosAlbert Einstein College of Medicine, Bronx, NY
Immunotherapy in Advanced NSCLC: The Case For/Against Bispecific Antibodies
Marina GarassinoUniversity of Chicago Medicine, Chicago, IL
Panel Discussion
Coffee Break
Session VIIILung Cancer
ModeratorTBD
Crafting Best Strategies for NSCLC with HER2 Mutation or Overexpression
Julia RotowDana-Farber Cancer Institute, Boston, MA
Building on Success: Optimizing Care for ALK and ROS1 NSCLC Across Stages
Narjust FlorezDana-Farber Cancer Institute, Boston, MA
How to Best Sequence Therapies for NSCLC with a Common EGFR Mutation
Justin GainorMassachusetts General Hospital, Boston, MA
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →